Natalie Vokes

28PUBLICATIONS
320CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 18, 2026
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

|Apr 23, 2026
Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

|Oct 06, 2025
Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial.

Maliazurina B Saad, Eman Showkatian, Vivek Verma

|Jul 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC.

Maliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong

|Mar 02, 2025
Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics.

Shreya Johri, Kevin Bi, Breanna M Titchen

|Feb 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

Pageof 5

Frequent Collaborators

15 joint publications

John Victor Heymach

15 joint publications

Don L Gibbons

15 joint publications

Jianjun Zhang

9 joint publications

Jack J Lee